Clinical management of patients with genetic obesity during COVID-19 pandemic: position paper of the ESE Growth & Genetic Obesity COVID-19 Study Group and Rare Endo-ERN main thematic group on Growth and Obesity.
Endocrine
; 71(3): 653-662, 2021 03.
Article
in English
| MEDLINE | ID: covidwho-1053106
ABSTRACT
This article aims to provide guidance on prevention and treatment of COVID-19 in patients with genetic obesity. Key principals of the management of patients with genetic obesity during COVID-19 pandemic for patients that have contracted COVID-19 are to be aware of possible adrenal insufficiency (e.g., POMC deficiency, PWS); a more severe course in patients with concomitant immunodeficiency (e.g., LEP and LEPR deficiency), although defective leptin signalling could also be protective against the pro-inflammatory phenotype of COVID-19; disease severity being masked by insufficient awareness of symptoms in syndromic obesity patients with intellectual deficit (in particular PWS); to adjust medication dose to increased body size, preferably use dosing in m2; the high risk of malnutrition in patients with Sars-Cov2 infection, even in case of obesity. Key principals of the obesity management during the pandemic are to strive for optimal obesity management and a healthy lifestyle within the possibilities of the regulations to prevent weight (re)gain and to address anxiety within consultations, since prevalence of anxiety for COVID-19 is underestimated.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Disease Management
/
Pandemics
/
COVID-19
/
Obesity
Type of study:
Observational study
/
Prognostic study
Limits:
Humans
Language:
English
Journal:
Endocrine
Journal subject:
Endocrinology
Year:
2021
Document Type:
Article
Affiliation country:
S12020-021-02619-y
Similar
MEDLINE
...
LILACS
LIS